Avenue Therapeutics, Inc. Common Stock
ATXI
ATXI was delisted on the 18th of March, 2025.
24 hedge funds and large institutions have $2.88M invested in Avenue Therapeutics, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 2 increasing their positions, 10 reducing their positions, and 16 closing their positions.
20% less funds holding
Funds holding: 30 → 24 (-6)
38% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 16
74% less capital invested
Capital invested by funds: $11.1M → $2.88M (-$8.23M)
80% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$345K |
| 2 |
Millennium Management
New York
|
+$321K |
| 3 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
+$153K |
| 4 |
E
Ergoteles
New York
|
+$133K |
| 5 |
VF
Virtu Financial
New York
|
+$114K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$1.38M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.09M |
| 3 |
State Street
Boston,
Massachusetts
|
-$873K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$276K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$232K |
ATXI Hedge Fund Activity: Q2 2021 in Review
24 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Avenue Therapeutics, Inc. Common Stock (ATXI) for Q2 2021, worth a combined $2.88M — down 74% from $11.1M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ATXI and 10 opened new positions — a net loss of 6 holders — while 10 trimmed existing stakes and 2 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $345K. The largest seller was BlackRock, cutting an estimated $1.38M.
- 24 institutional investors held Avenue Therapeutics, Inc. Common Stock (ATXI) as of Q2 2021, down from 30 in Q1 2021.
- Funds reported $2.88M of Avenue Therapeutics, Inc. Common Stock stock for Q2 2021, down 74% quarter-over-quarter.
- 10 funds opened new Avenue Therapeutics, Inc. Common Stock positions in Q2 2021 and 16 closed out, a net change of -6 holders.
- The largest Avenue Therapeutics, Inc. Common Stock buyer in Q2 2021 was Renaissance Technologies, an estimated $345K added.
- The largest Avenue Therapeutics, Inc. Common Stock seller in Q2 2021 was BlackRock, an estimated $1.38M sold.
Based on aggregated 13F filings for Q2 2021.